152 related articles for article (PubMed ID: 19918651)
1. [Basal-like breast cancers: clinicopathological features and outcome].
De Brot M; Soares FA; Stiepcich MM; Cúrcio VS; Gobbi H
Rev Assoc Med Bras (1992); 2009; 55(5):529-34. PubMed ID: 19918651
[TBL] [Abstract][Full Text] [Related]
2. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
Dabbs DJ; Chivukula M; Carter G; Bhargava R
Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011
[TBL] [Abstract][Full Text] [Related]
3. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
4. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
6. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
7. [Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?].
Mainka P; Kahlert S; Kirchner T; Mayr D; Diebold J
Pathologe; 2008 Nov; 29 Suppl 2():363-9. PubMed ID: 18807040
[TBL] [Abstract][Full Text] [Related]
8. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
Paredes J; Lopes N; Milanezi F; Schmitt FC
Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107
[TBL] [Abstract][Full Text] [Related]
9. [Morphological features of basal-like subtype invasive carcinoma of breast].
Gao LX; Yang GZ; Ding HY; Li L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
[TBL] [Abstract][Full Text] [Related]
10. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
11. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
12. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
13. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
[TBL] [Abstract][Full Text] [Related]
14. Prognostic markers in triple-negative breast cancer.
Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
[TBL] [Abstract][Full Text] [Related]
15. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.
Bryan BB; Schnitt SJ; Collins LC
Mod Pathol; 2006 May; 19(5):617-21. PubMed ID: 16528377
[TBL] [Abstract][Full Text] [Related]
16. c-erbB-2 and the "triple-state" in early breast carcinomas.
Sivridis E; Stamos C; Fiska A; Nikolettos N; Koukourakis MI; Giatromanolaki A
Med Oncol; 2010 Sep; 27(3):578-84. PubMed ID: 19548127
[TBL] [Abstract][Full Text] [Related]
17. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.
Sasa M; Bando Y; Takahashi M; Hirose T; Nagao T
J Surg Oncol; 2008 Jan; 97(1):30-4. PubMed ID: 17929254
[TBL] [Abstract][Full Text] [Related]
18. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.
Niwińska A; Olszewski W; Murawska M; Pogoda K
J Neurooncol; 2011 Dec; 105(3):547-53. PubMed ID: 21656328
[TBL] [Abstract][Full Text] [Related]
20. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]